Published in Br J Pharmacol on July 10, 2017
Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol (2010) 17.30
The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res (2015) 10.66
TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol (2007) 6.34
Liver cirrhosis. Lancet (2008) 6.11
The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol (2015) 5.96
Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol (2015) 5.43
Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol (2015) 4.46
Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov (2012) 4.30
The role of TGFbeta1 in initiating hepatic stellate cell activation in vivo. J Hepatol (1999) 2.35
TGF-β in progression of liver disease. Cell Tissue Res (2011) 2.22
Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. Hepatology (2000) 1.84
Hepatic fibrosis: Concept to treatment. J Hepatol (2015) 1.68
The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors. Br J Pharmacol (2015) 1.66
Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma. Cancer Res (2014) 1.49
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther (2015) 1.33
Id1 is a critical mediator in TGF-beta-induced transdifferentiation of rat hepatic stellate cells. Hepatology (2006) 1.28
Transforming growth factor-β signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1. Gastroenterology (2013) 1.19
Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies. Nat Protoc (2010) 1.18
Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model. Br J Clin Pharmacol (2014) 1.16
Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis. Hepatology (2005) 1.13
Liver transplantation: past, present and future. Nat Rev Gastroenterol Hepatol (2013) 1.11
Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers. Hepatology (1997) 1.06
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Invest New Drugs (2014) 1.04
Hsp47 as a collagen-specific molecular chaperone. Methods Enzymol (2011) 1.02
Inhibition of fibronectin deposition improves experimental liver fibrosis. J Hepatol (2014) 0.99
Matrix metalloproteinase-13 promotes recovery from experimental liver cirrhosis in rats. Pathobiology (2011) 0.97
Gene expression analysis of murine and human osteoarthritis synovium reveals elevation of transforming growth factor β-responsive genes in osteoarthritis-related fibrosis. Arthritis Rheumatol (2014) 0.95
Precision-cut liver slices: a tool to model the liver ex vivo. J Hepatol (2013) 0.94
Expression of HSP47, a collagen-specific chaperone, in normal and diseased human liver. Lab Invest (2005) 0.90
Post-transcriptional regulation of alpha-smooth muscle actin determines the contractile phenotype of Dupuytren's nodular cells. J Cell Physiol (2010) 0.88
The effect of antifibrotic drugs in rat precision-cut fibrotic liver slices. PLoS One (2014) 0.87
Interactions of heat shock protein 47 with collagen and the stress response: an unconventional chaperone model? Life Sci (2010) 0.87
Distribution of collagen types I, III, and V in fibrotic and neoplastic human liver. Acta Pathol Jpn (1984) 0.85
Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. Oncotarget (2015) 0.85
Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. Hepatology (2015) 0.85
ALK1-Smad1/5 signaling pathway in fibrosis development: friend or foe? Cytokine Growth Factor Rev (2013) 0.82
Precision-cut human kidney slices as a model to elucidate the process of renal fibrosis. Transl Res (2015) 0.79
Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts. Cell Oncol (Dordr) (2015) 0.79
Organ- and species-specific biological activity of rosmarinic acid. Toxicol In Vitro (2016) 0.77
Distribution of collagen type I and type III and of two collagenous components of basement membranes in the human liver. Pathol Res Pract (1980) 0.76
TIMP-1 in patients with cirrhosis: relation to liver dysfunction, portal hypertension, and hemodynamic changes. Scand J Gastroenterol (2014) 0.76
Human precision-cut liver slices as a model to test antifibrotic drugs in the early onset of liver fibrosis. Toxicol In Vitro (2016) 0.76
Novel TGF-β inhibitors ready for prime time in onco-immunology. Oncoimmunology (2016) 0.75
Liver resection combined with local ablation: where are the limits? Dig Surg (2011) 0.84
Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease. Aliment Pharmacol Ther (2017) 0.75